Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
9.72
-0.84 (-7.95%)
At close: Dec 5, 2025, 4:00 PM EST
9.19
-0.53 (-5.45%)
After-hours: Dec 5, 2025, 7:58 PM EST
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
12.26M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SNSE News
- 22 days ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - GlobeNewsWire
- 7 weeks ago - Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Sensei (SNSE) Q2 Loss Narrows 31% - The Motley Fool
- 4 months ago - Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - GlobeNewsWire